vs

Side-by-side financial comparison of MONARCH CASINO & RESORT INC (MCRI) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $136.6M, roughly 1.5× MONARCH CASINO & RESORT INC). MONARCH CASINO & RESORT INC runs the higher net margin — 20.2% vs -62.0%, a 82.2% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 8.9%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 3.2%).

The Atlantis Casino Resort Spa is a hotel and casino located in Reno, Nevada, United States. It is owned and operated by Monarch Casino & Resort, Inc. Its three hotel towers have a combined 824 guest rooms and suites. The casino floor spans 64,814 sq ft. Often known simply as "Atlantis," it is one of Reno's most profitable and luxurious properties, competing directly with Peppermill Hotel Casino and Grand Sierra Resort for customers. Nearly $150 million has been spent on upgrading the facility.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MCRI vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.5× larger
RARE
$207.3M
$136.6M
MCRI
Growing faster (revenue YoY)
RARE
RARE
+17.0% gap
RARE
25.9%
8.9%
MCRI
Higher net margin
MCRI
MCRI
82.2% more per $
MCRI
20.2%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
3.2%
MCRI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MCRI
MCRI
RARE
RARE
Revenue
$136.6M
$207.3M
Net Profit
$27.6M
$-128.6M
Gross Margin
Operating Margin
25.6%
-54.7%
Net Margin
20.2%
-62.0%
Revenue YoY
8.9%
25.9%
Net Profit YoY
38.9%
3.5%
EPS (diluted)
$1.52
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MCRI
MCRI
RARE
RARE
Q1 26
$136.6M
Q4 25
$140.0M
$207.3M
Q3 25
$142.8M
$159.9M
Q2 25
$136.9M
$166.5M
Q1 25
$125.4M
$139.3M
Q4 24
$134.5M
$164.6M
Q3 24
$137.9M
$139.5M
Q2 24
$128.1M
$147.0M
Net Profit
MCRI
MCRI
RARE
RARE
Q1 26
$27.6M
Q4 25
$22.9M
$-128.6M
Q3 25
$31.6M
$-180.4M
Q2 25
$27.0M
$-115.0M
Q1 25
$19.9M
$-151.1M
Q4 24
$4.2M
$-133.2M
Q3 24
$27.6M
$-133.5M
Q2 24
$22.7M
$-131.6M
Gross Margin
MCRI
MCRI
RARE
RARE
Q1 26
Q4 25
20.8%
Q3 25
26.7%
Q2 25
25.5%
Q1 25
20.2%
Q4 24
2.9%
Q3 24
25.6%
Q2 24
23.0%
Operating Margin
MCRI
MCRI
RARE
RARE
Q1 26
25.6%
Q4 25
21.3%
-54.7%
Q3 25
27.1%
-106.9%
Q2 25
25.8%
-64.8%
Q1 25
20.4%
-102.6%
Q4 24
3.1%
-74.3%
Q3 24
25.5%
-94.6%
Q2 24
22.9%
-79.1%
Net Margin
MCRI
MCRI
RARE
RARE
Q1 26
20.2%
Q4 25
16.4%
-62.0%
Q3 25
22.1%
-112.8%
Q2 25
19.7%
-69.0%
Q1 25
15.8%
-108.5%
Q4 24
3.1%
-80.9%
Q3 24
20.0%
-95.7%
Q2 24
17.7%
-89.5%
EPS (diluted)
MCRI
MCRI
RARE
RARE
Q1 26
$1.52
Q4 25
$1.25
$-1.28
Q3 25
$1.69
$-1.81
Q2 25
$1.44
$-1.17
Q1 25
$1.05
$-1.57
Q4 24
$0.25
$-1.34
Q3 24
$1.47
$-1.40
Q2 24
$1.19
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MCRI
MCRI
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$120.1M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$549.8M
$-80.0M
Total Assets
$725.2M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MCRI
MCRI
RARE
RARE
Q1 26
$120.1M
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$150.6M
Q2 24
$480.7M
Stockholders' Equity
MCRI
MCRI
RARE
RARE
Q1 26
$549.8M
Q4 25
$537.7M
$-80.0M
Q3 25
$558.4M
$9.2M
Q2 25
$539.2M
$151.3M
Q1 25
$535.6M
$144.2M
Q4 24
$517.7M
$255.0M
Q3 24
$513.3M
$346.8M
Q2 24
$498.4M
$432.4M
Total Assets
MCRI
MCRI
RARE
RARE
Q1 26
$725.2M
Q4 25
$712.8M
$1.5B
Q3 25
$725.4M
$1.2B
Q2 25
$705.8M
$1.3B
Q1 25
$712.1M
$1.3B
Q4 24
$691.6M
$1.5B
Q3 24
$671.1M
$1.5B
Q2 24
$672.4M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MCRI
MCRI
RARE
RARE
Operating Cash FlowLast quarter
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MCRI
MCRI
RARE
RARE
Q1 26
Q4 25
$38.1M
$-99.8M
Q3 25
$56.0M
$-91.4M
Q2 25
$34.1M
$-108.3M
Q1 25
$36.5M
$-166.5M
Q4 24
$37.8M
$-79.3M
Q3 24
$40.3M
$-67.0M
Q2 24
$24.3M
$-77.0M
Free Cash Flow
MCRI
MCRI
RARE
RARE
Q1 26
Q4 25
$32.2M
$-100.8M
Q3 25
$53.5M
$-92.7M
Q2 25
$26.0M
$-110.7M
Q1 25
$16.6M
$-167.8M
Q4 24
$26.2M
$-79.5M
Q3 24
$35.4M
$-68.6M
Q2 24
$11.0M
$-79.0M
FCF Margin
MCRI
MCRI
RARE
RARE
Q1 26
Q4 25
23.0%
-48.6%
Q3 25
37.5%
-58.0%
Q2 25
19.0%
-66.5%
Q1 25
13.3%
-120.5%
Q4 24
19.5%
-48.3%
Q3 24
25.7%
-49.2%
Q2 24
8.5%
-53.7%
Capex Intensity
MCRI
MCRI
RARE
RARE
Q1 26
Q4 25
4.2%
0.5%
Q3 25
1.7%
0.8%
Q2 25
5.9%
1.5%
Q1 25
15.8%
1.0%
Q4 24
8.6%
0.1%
Q3 24
3.6%
1.2%
Q2 24
10.4%
1.4%
Cash Conversion
MCRI
MCRI
RARE
RARE
Q1 26
Q4 25
1.66×
Q3 25
1.77×
Q2 25
1.26×
Q1 25
1.84×
Q4 24
8.98×
Q3 24
1.46×
Q2 24
1.07×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MCRI
MCRI

Casino$79.7M58%
Food and beverage$31.7M23%
Hotel$19.0M14%
Other$6.1M5%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons